Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharmaâs clinical stage drug candidate X842 takes a new approach to provide improved management of esophagitis and GERD symptoms.
Location: Sweden, Stockholm
Total raised: $26.47M
Investors 2
| Date | Name | Website |
| 23.07.2023 | Irrus Inve... | irrusinves... |
| - | Eir Ventur... | eirventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.03.2020 | - | $26.47M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 20.05.2022 | Trill Impact leads the 240 MSEK venture financing round in C... | Trill Impact leads the 240 MSEK venture financing round in Cinclus Pharma Fri, May 20, 2022 08:00 C... | news.cisio... |
| 29.11.2021 | Cinclus Pharma Appoints Gösta Hiller as Chief Operating Offi... | Cinclus Pharma Appoints Gösta Hiller as Chief Operating Officer Mon, Nov 29, 2021 08:00 CET Stockho... | news.cisio... |
| 06.09.2021 | Cinclus Pharma receives approval of the International Nonpro... | Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate f... | news.cisio... |
| 27.08.2021 | Cinclus Pharma Appoints Maria Engström as Chief Financial Of... | Cinclus Pharma Appoints Maria Engström as Chief Financial Officer Fri, Aug 27, 2021 08:00 CET Stock... | news.cisio... |
| 18.08.2021 | Cinclus Pharma announces the first patient randomized in the... | Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD. Wed, A... | news.cisio... |
| 05.03.2020 | Cinclus Pharma Raises SEK250M in Funding | Cinclus Pharma Holding AB, a Swedish developer of a novel treatment against gastroesophageal reflux ... | finsmes.co... |